poisar

Stocks · News reference

Lifeward Announces Publication Of Long-Term Study On User Experience Of Its ReWalk Personal Exoskeleton In 'Spinal Cord Series And Cases'

Benzinga Newsdesk

Publication of an independent, investigator-initiated peer-reviewed study which provides long-term real-world evidence on the safety, utilization and user experience of the ReWalk® Personal Exoskeleton in individuals

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

LFWD
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  2. SEC EDGAR

    8-K filing — Lifeward Ltd. (LFWD)

    Filed: 2026-10-08 AccNo: 0001178913-26-004746 Size: 190 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

    LFWD
  3. Lifeward Ltd.

    Peer-Reviewed Study of Lifeward’s ReWalk® Exoskeleton Reports Significant Improvements in Daily Activity Performance, Satisfaction, and Pain

    An independent peer-reviewed study published in the Internet Journal of Allied Health Sciences and Practice demonstrates that individuals with chronic spinal cord injury using Lifeward's ReWalk personal exoskeleton showed significant improvements in daily activity performance, satisfaction, and reduced pain compared to wheelchair use. All 12 study participants successfully performed kitchen tasks while standing, 10 performed grooming tasks, and 8 reported improvements in bowel and bladder function. The findings support ReWalk's clinical value as Lifeward expands commercial distribution and reports 13% year-over-year sales growth to $2.5 million in Q2 2026.

    LFWD